Short answer

Terns Pharmaceuticals, Inc. (TERN) filed its fiscal 2024 10-K annual report with the SEC on Mar 20, 2025.

Top risk flagged: Regulatory risk: compliance with Section 404 of Sarbanes-Oxley Act may cause significant costs and penalties

FY2024 key financial metrics · XBRL

Source: XBRL data from the Terns Pharmaceuticals, Inc. (TERN) FY2024 10-K on SEC EDGAR. USD.

AI summary of each section, grounded in the filing text

Core business: clinical-stage biopharmaceutical developing small-molecule therapies for serious diseases including oncology (CML) and obesity
New emphasis on TERN-701 allosteric BCR-ABL inhibitor for CML with positive Phase 1 data and FDA orphan drug designation in March 2024
Strategic focus shifted to best-in-class allosteric TKIs targeting BCR-ABL myristoyl pocket to overcome limitations of active-site TKIs and asciminib
Positive Phase 1 CARDINAL trial enrolled 19 patients, with 88% of baseline >1% BCR-ABL transcript patients showing treatment response, no dose-limiting toxicities
Noteworthy safety profile for TERN-701: no grade 3+ treatment-related adverse events or discontinuations, with once-daily dosing attractive for long-term CML therapy

No revenue from product sales in FY 2024 and 2023; potential milestone revenue from TERN-701 license in Greater China
Net loss $88.9M in 2024 vs $90.2M in 2023; operating expenses $101.9M vs $102.6M; R&D expenses rose 10% to $70.1M, G&A expenses decreased 19% to $31.8M
R&D spending highest on TERN-701 ($15.8M) and TERN-601 ($15.5M); steep decline in TERN-501 expenses from $17.8M to $0.9M
Cash, cash equivalents and marketable securities $358.2M at year-end; net cash used in operations $70.0M; raised $161.9M in Sept 2024 public offering
Management expects expenses and operating losses to remain significant; plans development milestones in CML and obesity; potential risks from capital needs and regulatory outcomes

Regulatory risk: compliance with Section 404 of Sarbanes-Oxley Act may cause significant costs and penalties
Macroeconomic threat: global economic downturn may weaken demand and delay payments for potential approved drugs
Supply chain vulnerability: potential supply disruptions from manufacturers and vendors during pandemics or public health events
Market disruption risk: competitive clinical trial failures or delays, impacting development against industry peers
Financial risk: net operating loss carryforwards usage limited by IRS Section 382 ownership change rules

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.